Draft Chapter 8 EU GMP Guide: Complaints, Quality Defects and Product Recalls

Comments from:

Name of organisation or individual

AESGP

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

When completed, this form should be sent to the European Medicines Agency electronically, in Word format (not PDF).

1. General comments

Stakeholder number	General comment (if any)	Outcome (if applicable)
(To be completed by the Agency)		(To be completed by the Agency)

2. Specific comments on text

Line number(s) of	Stakeholder number	Comment and rationale; proposed changes	Outcome
the relevant text (e.g. Lines 20- 23)	(To be completed by the Agency)	(If changes to the wording are suggested, they should be highlighted using 'track changes')	(To be completed by the Agency)
Principle, 2 nd paragraph		Comment: Faulty manufacture is a very general term and should be explained, if used. Critical GMP failures are not referenced, but may be (as well as non-compliance with the marketing authorization) a relevant source for serious quality defects. Proposed change (if any): Delete faulty manufacture or further explain, add critical GMP failures	
Item 8.30		Comment: "out-of-office hours": Availability in out-of-office hours must be clearly defined by the companies and should be checked via Mock recall. However, a blind attempt to reach everybody during out-of-the office hours is not considered productive. Proposed change (if any): Add "Out-of -the office hours are included to check whether the established emergency system works or needs to be improved".	

Please add more rows if needed.